BHT 3009

Drug Profile

BHT 3009

Alternative Names: BHT-3009; BHT-300904

Latest Information Update: 20 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayhill Therapeutics
  • Class DNA vaccines
  • Mechanism of Action Immunosuppressants; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Multiple sclerosis

Most Recent Events

  • 03 Feb 2011 The product is still in phase II development for Multiple sclerosis
  • 15 Oct 2010 Efficacy data from a phase II trial in Multiple sclerosis released by Bayhill Therapeutics
  • 09 Oct 2007 Top-line results from a phase IIb trial (BHT-3009-03) in patients with relapsing-remitting multiple sclerosis added to the adverse events and Neurological Disorders therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top